Abstract
Tissue prostaglandin (PG) content and production by human breast cancers were measured in 24 human mammary carcinoma specimens. The 5 compounds studied were PGE1, PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TXB2. The tissue content of all 5 compounds was higher in neoplastic tissue in comparison with the paired noncancerous breast tissue. However, microsomal PG synthetase activity in vitro in noncancerous and neoplastic breast tissue was comparable. Increased thromboxane formation was associated with three clinical variables--tumour size, axillary lymph node metastases and distant metastasis. A lesion negative for either oestrogen or progesterone receptor content tended to produce more TXB2 but lower PGE2 and 6-keto-PGF1 alpha. Results obtained in this pilot study may provide clues as to what direction future larger studies could take in the search for reliable prognostic indicators for breast cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bennett A., Berstock D. A., Raja B., Stamford I. F. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers [proceedings]. Br J Pharmacol. 1979 Jul;66(3):451P–451P. [PMC free article] [PubMed] [Google Scholar]
- Bennett A., Charlier E. M., McDonald A. M., Simpson J. S., Stamford I. F., Zebro T. Prostaglandins and breast cancer. Lancet. 1977 Sep 24;2(8039):624–626. doi: 10.1016/s0140-6736(77)92496-5. [DOI] [PubMed] [Google Scholar]
- Bennett A., McDonald A. M., Simpson J. S., Stamford I. F. Breast cancer, prostaglandins, and bone metastases. Lancet. 1975 May 31;1(7918):1218–1220. doi: 10.1016/s0140-6736(75)92197-2. [DOI] [PubMed] [Google Scholar]
- Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
- Honn K. V., Busse W. D., Sloane B. F. Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochem Pharmacol. 1983 Jan 1;32(1):1–11. doi: 10.1016/0006-2952(83)90644-5. [DOI] [PubMed] [Google Scholar]
- Honn K. V., Cicone B., Skoff A. Prostacyclin: a potent antimetastatic agent. Science. 1981 Jun 12;212(4500):1270–1272. doi: 10.1126/science.7015512. [DOI] [PubMed] [Google Scholar]
- Horrobin D. F. The reversibility of cancer: the relevance of cyclic AMP, calcium, essential fatty acids and prostaglandin E1. Med Hypotheses. 1980 May;6(5):469–486. doi: 10.1016/0306-9877(80)90099-7. [DOI] [PubMed] [Google Scholar]
- Karmali R. A., Muse P., Allen G., Louis T. Macrophage production of prostaglandins: effects of fetal calf serum and diazepam. Use of an improved method for extracting 6-keto-PGF1 alpha. Prostaglandins Leukot Med. 1982 Jun;8(6):565–577. [PubMed] [Google Scholar]
- Karmali R. A. Review: prostaglandins and cancer. Prostaglandins Med. 1980 Jul;5(1):11–28. doi: 10.1016/0161-4630(80)90086-5. [DOI] [PubMed] [Google Scholar]
- Kibbey W. E., Bronn D. G., Minton J. P. Prostaglandin synthetase and prostaglandin E2 levels in human breast carcinoma. Prostaglandins Med. 1979 Feb;2(2):133–139. doi: 10.1016/0161-4630(79)90048-x. [DOI] [PubMed] [Google Scholar]
- Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980 May;64(5):1061–1070. [PubMed] [Google Scholar]
- Seyberth H. W., Segre G. V., Morgan J. L., Sweetman B. J., Potts J. T., Jr, Oates J. A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975 Dec 18;293(25):1278–1283. doi: 10.1056/NEJM197512182932502. [DOI] [PubMed] [Google Scholar]